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Cell invasionProtease Nexin-1 (PN-1) or Serpine2 is a physiological regulator of extracellular proteases as thrombin and
urokinase (uPA) in the brain. Besides, PN-1 is also implicated in some human cancers and further identiﬁed
as a substrate for Matrix Metalloproteinase (MMP)-9, a key enzyme in tumor invasiveness. Our aim was to
study the role of PN-1 in themigration and invasive potential of glioma cells, using the rat C6 glioma cell line
as stable clones transfected with pAVU6+27 vector expressing PN-1 short-hairpin RNA. We ﬁnd that PN-1
knockdown enhanced the in vitro migration and invasiveness of C6 cells which also showed a strong
gelatinolytic activity by in situ zymography. PN-1 silencing did not alter prothrombin whereas increased
uPA, MMP-9 and MMP-2 expression levels and gelatinolytic activity in a conditioned medium from stable
C6 cells. Selective inhibitors for MMP-9 (Inhibitor I), MMP-2 (Inhibitor III) or exogenous recombinant
PN-1 added to the culture medium of C6 silenced cells restored either the migration and invasive ability
or gelatinolytic activity thus validating the speciﬁcity of PN-1 silencing strategy. Phosphorylation levels of
extracellular signal-related kinases (Erk1/2 and p38 MAPK) involved in MMP-9 and MMP-2 signaling were
increased in PN-1 silenced cells. This study shows that PN-1 affects glioma cell migration and invasiveness
through the regulation of uPA and MMP-9/2 expression levels which contribute to the degradation of extracellular
matrix during tumor invasion.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Protease Nexin-1 (PN-1) or Serpine2, is a 44 kDa serine protease
inhibitor that belongs to the serpin super family [1].Whilemany serpinsP-2, Matrix Metalloproteinase-9
hairpin RNA; ECM, extracellular
lipoprotein receptor-related pro-
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rcone).are found in plasma, PN-1 is present mainly in the extracellular matrix
(ECM) and it is secreted bymanydifferent cell types, includingﬁbroblasts
[2], myoblasts [3], and vascular smoothmuscle cells [4]. PN-1 inhibits the
enzyme activity of extracellular proteases including thrombin, urokinase,
urokinase Plasminogen Activator (uPA), tissue plasminogen activator
(tPA) and plasmin [5,6] by a suicide substrate mechanism mediated by
the formation of a covalent complex with the target protease [7]. The
serpin–protease complex binds to the low-density lipoprotein receptor-
related protein (LRP) that mediates its endocytosis and degradation,
thus providing a localized mechanism for the inhibition and clearing of
the protease from the extracellular environment [6].
PN-1 was ﬁrst identiﬁed as glia-derived nexin (GDN) [5] in the
central nervous system (CNS)where it is primarily secreted by astrocytes
[8], glial [9], and neuronal [10] cells. In the brain, PN-1 is the main
physiological modulator of thrombin-mediated processes such as neurite
outgrowth [11], proteolytic damage and apoptosis in brain injury [12,13].
Many evidences have shown that the balance between extra-cellular ser-
ine proteases and their cognate serpins play a role in many physiological
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progression [16].
Among PN-1 targets, thrombin is also known to regulate tumor cell
invasion and metastasis [17] and uPA is critically involved in tumor
angiogenesis andmetastasis [18]. In addition, uPA controls cellmigration
through its ability to convert plasminogen into plasmin [19] and is
involved in the maturation of other proteins, including Matrix Metallo-
proteinases (MMPs) and growth factors [20]. Also members of MMP
family, especially MMP-2 and MMP-9, known as gelatinases A and B
[21], are critically involved in tumor angiogenesis and metastasis and
also found overexpressed in malignant tissues [22]. In human tumors,
the overexpression of MMP-9 and uPA have been associated with cancer
progression [23] and poor prognosis in several cancer types [24].
In the last years, the overexpression of PN-1 mRNA in some cancer
cell lines and human cancers, including breast [25] and pancreatic
tumors [26], and oral squamous carcinomas [27], has been correlated
to metastatic process.
Further, in 2008, Xu et al. [28] reported that PN-1 is a substrate for
MMP-9, thus suggesting a new function for this serpin, that may have
a regulatory role onMatrixMetalloproteinase/s in the ECM [29]. Several
authors explored the functional role of PN-1 in tumor biology and the
relationship with MMP-9 and uPA, that are key enzymes in tissue
remodeling and cancer progression by promoting the degradation of
ECM components [30,31]. However, controversial results have been
reported in diverse tumor types and system models.
Up-regulation of PN-1 has been associatedwith the invasive potential
of pancreatic cancer cells S2-028 in a nude mice xenograft model
whereas no signiﬁcant effects were observed using matrigel invasion
and zymography assays [26]. In prostate cancer cells DU-145 and
PC-3, PN-1 can affect the anti-invasive activity of the serine protease
prostasin [32].
Injections in nudemice of 4T1mammary cancer cells, in which PN-1
had been silenced, did not affect primary tumor outgrowth whereas
impaired metastatic potential that could be restored by coexpressing
soluble MMP-9 [33]. Thus, these authors postulated a mechanism
whereby PN-1, complexed with target proteases, binds the LRP-1
receptor thereby controlling MMP-9 expression and metastatic spread
via Erk signaling.
In contrast, in 2010, Xu et al. [29] reported that prostate cancer cells,
PC3-ML, overexpressing PN-1 or treated with MMP-9 shRNA, had
reduced cell invasion in matrigel assay, through the inhibition of uPA
activity. In addition, increased PN-1 amounts and inhibition of uPA
activity were induced by the downregulation of MMP-9 in PC3-ML
cells and in the tissue of MMP-9 deﬁcient mice, consistent with PN-1
degradation by MMP-9 [28]. These authors indicated an anti-invasive
function of PN-1 and showed a novel molecular pathway in which
MMP-9 regulates uPA activity and tumor cell invasion through the
cleavage of PN-1 [28].
Gliomas are among the most common type of human primary brain
tumors with an infaust prognosis [34]. Since no studies are available on
PN-1 functions in glioma tumors, this study was designed to investigate
the role of PN-1 on migration and invasion ability on cells derived from
rat glioma. The rat C6 glioma cell line [35] was chosen as an in vitro
model system because these cells maintain many characteristics of
“glioblastoma multiforme” (GBM) [36] and constitutively secrete PN-1
[9]. We used a vector-based (pAVU6+27) [37] RNA interference
(RNAi) approach [38] to silence PN-1 expression in C6 cells. Selected
clones were tested for migration and invasion ability using migration
and matrigel invasion assays and the results were compared to control
unsilenced cells, transfected with the empty vector. We have analyzed
the effects of PN-1 silencing on expression levels of its target proteases,
such as thrombin, uPA andMMP-9.Moreover, our study also focused on
the gelatinase A, MMP-2, which is the metalloproteinase closely related
toMMP-9 for structure and biological functions. Thrombin, uPA,MMP-9
and MMP-2 protein and mRNA expression levels were evaluated either
by western blotting or semiquantitative RT-PCR analysis, respectively.MMP-9, MMP-2 and uPA enzyme activities were assessed by SDS-
PAGE zymography analysis. Our results demonstrated a correlation
between the enhancement of migration and invasion ability and
up-regulation of uPA, MMP-9 and MMP-2 expression levels triggered
by PN-1 silencing in C6 glioma cells. In addition, we determined the
phosphorylation levels of the extracellular signal-related kinases,
Erk1/2 and p38 MAPK [39], known to be implicated in the migration
and invasion ability of various cell types, through the activation of
plasminogen activators (PAs) and MMPs [33,40,41].
2. Materials and methods
2.1. Construction of pAVU6+27-siPN-1 expression vectors
Three siRNA sequences targeting rat PN-1 were selected using
the Ambion and Genescript web-based (www.ambion.com; www.
genescript.com) criteria. The selection was performed by identifying
target sites along the open reading frame of rat PN-1 gene sequence
(NCBI, Reference Sequence: NM_019197.1; Supplementary Fig. 1A).
The RNAi sequences were the following:
D31: 5′-AGGAACCAUGAAUUGGCAU-3′, spanning nucleotides 118 to
136;
2G: 5′-CCACAGUGACUUUAUCCUC-3′, spanning nucleotides 156 to
174;
A7: 5′-GUCACUCGAGGAACUAGGC-3′ spanning nucleotides 199 to
216.
The correspondingDNA sequenceswere chemically synthesized as a
couple of complementary oligos (CEINGE, Naples, Italy) containing also
a SalI at the 5′ end and XbaI at the 3′ end (Supplementary Fig. 1B)
restriction sites, used for cloning in the pAVU6+27 vector [37] that
contains one U6 promoter cassette and the ﬁrst 27 nucleotides of
human U6 RNA (Supplementary Fig. 2A). The RNAi sequences and the
secondary structure of hairpin oligos are reported in Supplementary
Fig. 2B.
For the cloning procedure, the two oligos of which above were
incubated at 95 °C for 30 min with annealing buffer (10 mM Tris–
HCl, pH 7.8, 100 mM NaCl), gradually cooled to room temperature
to anneal shDNAs. These were then inserted into the SalI and XbaI
restriction sites of pAVU6+27 vector previously digested with
these endonucleases.
The resulting shRNA expression vectors, named pAVU6+PN1-
D31, pAVU6+PN1-2G and pAVU6+PN1-A7 were transformed into
Escherichia coli strain DH5α. Transformants were grown over-
night and puriﬁed plasmids were ﬁrst subjected to 1.5% agarose
gel electrophoresis for restriction analysis prior DNA sequence
determination.
2.2. Cell culture, DNA transfection and generation of C6 stable cell clones
The C6 rat glioblastoma cell line [35] (American Type Culture Collec-
tion, ATCC, CCL-107)was cultured inDulbecco'smodiﬁedEagle'smedium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 1.5 mM L-glutamine, 50 IU/ml penicillin and 50 μg/ml streptomy-
cin. Human glioblastoma (A 172), glioblastoma–astrocytoma (U-87 MG,
U-373 MG) and astrocytoma (SW-1088) cell lines were provided by the
cell culture facility and biobank of CEINGE-Biotecnologie Avanzate,
Naples, Italy. A 172 cells were cultured in DMEM supplemented with
10% heat-inactivated FBS, 2 mM L-glutamine, 50 IU/ml penicillin and
50 μg/ml streptomycin; U-87 MG and U-373 MG cells in Eagle's minimal
essential medium (EMEM) with 10% FBS, 2 mM L-glutamine; SW-1088
cells were grown in Leibovitz's L-15 medium with 10% FBS, 2 mM L-
glutamine. The cells were maintained at 37 °C in a 5% CO2 atmosphere
and sub-conﬂuent cultures (70–80%) were splitted 1:3 to 1:6 twice a
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Fig. 1. Expression of PN-1 protein levels in human brain cancer cell lines and silencing of
PN-1 expression in rat C6 glioblastoma cells. Cells grown sub-conﬂuent were switched
to the serum-free medium for 48 h, then conditioned media were collected and the cells
harvested for the preparation of total protein extracts or total RNA. Conditioned media
were concentrated by ultraﬁltration, volumes corresponding to equal amounts of cellular
proteins (100 μg)were loaded onto 12% SDS-PAGE followed by PN-1 immunostaining and
signalswere revealed by enhanced chemiluminescence (ECL). (A) Representativewestern
blotting analysis on cell conditioned media from rat C6 and human A172, U-87 MG,
SW-1088 and U-373 MG cell lines. (B) Densitometric analysis of PN-1 expression
levels in brain cancer cell lines. (C) Representative western blotting analysis on cell
conditioned media from wild type and stable C6 cells (Ctrl, A7.6, D31.6, 2G.2 and 2G.3)
transfectedwith recombinant shRNA PN-1 expression vectors. (D) Densitometric analysis
of PN-1 expression levels in wild type and stable C6 cells, as indicated. (E) RT-qPCR
analysis of PN-1 mRNA levels on total RNA extracted from wild type C6 cells and stable
clones. Fold expression in PN-1 protein and mRNA levels were calculated vs unsilenced
(Ctrl) cells, set as 1. In all panels, each bar represents the mean ± SEM of at least three
different determinations. Values statistically different from those of control cells were
indicated. (⁎p b 0.05; §p b 0.01; #p b 0.001). For other details see the “Materials and
methods” section.
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density with a culture medium.
For DNA transfection, C6 cells were seeded subconﬂuent on 60-mm
plates; 24 h after plating, cotransfection was carried out using 4 μg of
each pAVU6+PN1-I plasmid and 1 μg of pTK-Hygro plasmid (cat. n.
631750, Clontech, Italy) using the calcium phosphate precipitation
technique [42]; 16 h after transfection, precipitates were washed off
and, to select stable transfected cell clones, a fresh medium containing
the lowest lethal concentration of Hygromycin B (0.5 mg/ml, cat. n.
sc-29067, Santa Cruz, Italy) was added. Cells transfected with empty
pAVU6+27 (4 μg) and pTK-Hygro (1 μg) vectors were used to generate
stable clones used as unsilenced control (Ctrl cells); untrasfected C6
cells were used as basal control. For each transfected plasmid, at least
8 stable cell clones were isolated and further ampliﬁed. After 24, 48
and 72 h following depletion of the antibiotic, cells were harvested
and the culture media were collected and assayed for the detection of
PN-1 expression level by western blotting analysis. Stable clones with
the lower level of protein secretion were chosen for further characteri-
zation. For rescue experiments, cells were exposed to a serum-free
medium containing exogenous recombinant PN-1 [43] added to a ﬁnal
concentration of 200 or 500 ng/ml for 48 h.
For the preparation of a conditioned medium, subconﬂuent cells
were grown in 100-mm plates in DMEM supplemented with 10%
FBS until conﬂuency, washed with phosphate-buffered saline (PBS,
pH 7.4) three times and then incubated in the serum-free medium.
After 48 h, the medium was collected, centrifuged at 6000 ×g for
20 min to remove cells and debris, and concentrated approximately
20-fold by centrifugation at 5000 ×g using Ultra-4, PLGC Ultracel-PL
Membrane, 10 kDa cut-off (cat. n. UFC801024, Merck Millipore, Italy)
at 4 °C. The volume of the concentrated medium was measured
and stored in aliquots at −80 °C until use. Aliquots of the concen-
trated medium corresponding to identical amount of cell proteins
(100 μg) were analyzed by western blotting and gelatin zymography
analysis.
2.3. Migration and matrigel invasion assays
Cell migration assay was performed using BD Falcon™ Cell Culture
Inserts (cat. n. 353097, BD Bioscience, Bedford, MA; 8 μm) in 24-well
culture plates. Cell invasion assay was performed by BD Falcon BioCoat
Matrigel Invasion Chambers (cat. n. 354480, BD Bioscience, BedfordMA;
8 μm). The cell culture inserts were rehydrated and prepared as
described in the manufacturer's instructions. Brieﬂy, 2 · 104 cells in
0.5 ml of DMEMwith 0.5% FBS were seeded in the upper chamber and
750 μl medium with 5% FBS was placed in the lower chamber. After
24 h, non-migrating cells in the upper chamber were removed with
the cotton swab and the cells at the bottom of the ﬁlters were ﬁxed
and stained with Diff-Quick kit (cat. n. B4132-1A, Becton-Dickinson).
After two washes with water, the inserts were allowed to air dry and
phase-contrast images were captured using a Zeiss Axiovert 40 CFL
inverted microscope (Carl Zeiss, Milan, Italy) (LD A-Plan 20×/0.30 Ph
1 objective). The microscope was equipped with a 12.1-megapixel
CCD digital video camera (Canon, PowerShot G9, Italy) with a digital
image software (Remote Capture DC, Canon). To assess cell migration
and invasion ability, the total number of cells was determined by
cell counting in ﬁve ﬁelds randomly selected per membrane. To
determine the role of MMP-9 and MMP-2 in effects induced by
PN-1 down-regulation, the selective MMP-9 (2-(N-benzyl-4-
methoxyphenylsulfonamido)-5-((diethylamino)methyl)-hydroxy-3-
methylbenzamide); MMP-9 Inhibitor I) [29,44,45] (cat. n. 444278,
Calbiochem, Italy) and MMP-2 (2-[isopropoxy)(1,1′-biphenyl-
4ylsulfonyl)-amino)]-N-hydroxyacetamide; MMP-2 Inhibitor III)
[46] (cat. n. 444288, Calbiochem, Italy) inhibitors were applied.
Migration and invasion assays were also performed adding to the
medium in the upper and lower compartments, 25 nM MMP-9
Inhibitor I or 60 nM MMP-2 Inhibitor III, concentrations that targetthe MMP-9 (IC50 value = 5 nM) or MMP-2 (IC50 value = 12 nM),
Rescue experiments were performed in the presence of 500 ng/ml
exogenous recombinant PN-1 [43].
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action and RT-PCR analyses
Total RNA was puriﬁed from C6 cells and stable clones using a
commercial kit (RNeasy mini kit, Qiagen, Valencia, CA, USA) including
treatment with DNase I to prevent genomic DNA contamination (Turbo
DNA-free Kit; cat. n. AM1907; Ambion, Foster City, CA) according to the
manufacturer's instructions. The concentration and purity of RNA were
determined spectrophotometrically by reading the absorbance at 260
and 280 nm. Total RNA (2 μg) was reverse-transcribed to cDNA byA Migration assay
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cells).using the SuperScript III First-Strand Synthesis System (cat. n. 18080-
051; Invitrogen, Italy), according to the manufacturer's protocol. Three
replicates were used for each sample.
For quantitative real-time PCR (qPCR) analysis, the Rn
01400467_m1 Assays-on-Demand Gene expression (Applied
Biosystems, Foster City, CA, USA) was used, which contains a primer
pair between exon 4 and exon 5 (amplicon of 79 bp) and a TaqMan
probe centered on nucleotide 809 (RefSeq NM_019197.1) conjugat-
ed to the 5′ with 6-FAM ﬂuorochrome and to the 3′ with the MGB–
NFQ.Invasion assay
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was analyzed with the Rn 00667869_m1 Assays-on-Demand Gene
expression (Applied Biosystems, Foster City, CA, USA), which contains
a primer pair between exon 4 and exon 5 (amplicon of 91 bp) and a
TaqMan probe centered on nucleotide 888 (RefSeq NM_031144.2)
conjugated to the 5′ with 6-FAM ﬂuorochrome and to the 3′ with the
MGB–NFQ.
Real-time PCR assays were carried out, in triplicate, for each
sample in a total reaction volume of 20 μl, which contained 12.5 μl
of TaqMan OneStep RT-PCR Master Mix, 1 μl of 20× Assays-on-
Demand Gene expression Assay Mix, 0.8 μl of a mixture ofA
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virus (0.25 U ﬁnal concentration) and RNase inhibitor (0.4 U/μl
ﬁnal concentration), 5 μl of total RNA template (10–100 ng) from
each cell culture, and 5.7 μl of RNase free water.
PCR conditions were as follows: cycling was preceded by heating at
48 °C for 30 min for RT, followed by a step at 95 °C for 10 min, then
40 cycles at 95 °C for 15 s, 60 °C for 60 s and 72 °C for 20 s. The cycle
threshold values were used to calculate the normalized expression of
PN-1 against β-actin. Real-time PCR was performed in the ABI Prism
7500 Sequence Detection System using a SYBR Green detection system
(cat. n. 170-8880; Bio-Rad Laboratories. Italy). Relative quantiﬁcation1.5
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according to Pfafﬂ [47]. By identifying the threshold cycle (CT) for the
expression of mRNA, the ΔCT for PN-1 was calculated and compared to
vector transfected control cells. The ΔCT was converted into a ratio
(target A/target B = 2−ΔCT) describing the comparison of the relative
expression of PN-1 (target A) to β-actin (target B) for each of the cell
lines. Levels of mRNA were calculated as fold-induction relative to Ctrl
cells using the 2−ΔΔCT method [48]. For semi-quantitative RT-PCR
analysis, cDNA (1 μl) was ampliﬁed using 1 μM of appropriate primers
and 2 units of Platinum Taq DNA Polymerase (Invitrogen Life Tech-
nologies, Italy) in a ﬁnal volume of 25 μl of the PCR buffer, containing
5 mMMgCl2 and 1 mM deoxyribonucleotide triphosphates. The PCR
reaction proceeded for 35 cycles in a DNA thermal cycler (Techgene,
Italy). Each ampliﬁcation cycle consisted of denaturing at 94 °C for
1 min, followed by annealing primers to target sequences for 1 min
at 56 °C for uPA and MMP-9; 54 °C for MMP-2 and 58 °C for β-
actin; ﬁnally, primer extension was carried out for 7 min at 72 °C.
The PCR products (uPA, 348 bp; MMP-2, 604 bp; MMP-9, 480 bp;
β-actin, 302 bp) were electrophoresed onto a 1.5% agarose gel
which was then stained with ethidium bromide and visualized
by UV transillumination. The primer sequences used for the PCR
reactions are the following:
uPA
forward 5′-GTGGAGAACCAGCCCTGGT-3′;
reverse 5′-GGCAGGCAGATGGTCTGTAT-3′ [49];
MMP-2
forward 5′-GTGCTGAAGGACACCCTCAAGAAGA-3′;
reverse 5′-GCATGTTGAAACTCTTCCTGCCGTT-3′ [50];
MMP-9
forward 5′-ACGGCAAGGATGGTCTACTG-3′;
reverse 5′-GTGACATTGACCCCCGTTGA-3′ [50];
β-actin
forward 5′-TCCTCCCTGGAGAAGAGCTA-3′;
reverse 5′-TCAGGAGGAGCAATGATCTTG-3′ [51].Ctrl Ctrl Ctrl
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(500 ng/ml). After 6 and 24 h, cells were ﬁxed and nuclei were stained with DAPI. Pictures w
ﬂuorescence (FITC) show gelatinolytic activity whereas nuclei (DAPI) appear in blue. Mer
FITC-gelatin ﬂuorescence intensity was performed in both controls and cells treated wit
triplicate. §p value b 0.03.2.5. In situ zymography
Glass coverslips (12mm)were coatedwithﬂuorescein isothiocyanate
(FITC)-gelatin (cat. n. D-12054, DQ™ gelatin, Molecular Probe) for in situ
zymography (ISZ) as reported [52]. 5 · 104 cells seeded onto FITC-gelatin
coated glass coverslips were kept in DMEMwith 10% FBS for 24 h; after
the incubation, the coverslips were washed three times with PBS and
serum-free DMEM was added to allow gelatin degradation. Rescue
experiments were performed in the presence of exogenous recombinant
PN-1 [43] (200 or 500 ng/ml) for 6 or 24 h. Finally, the cells were ﬁxed in
4% paraformaldehyde mounted on slides with Vectashield® containing
1.5 μg/ml 4′6-diamidino-2-phenylindole (DAPI) (VECTOR Laboratories)
to visualize the nuclei. Images were captured by using a Zeiss LSM
510 meta confocal microscope equipped with an oil immersion
plan Apochromat 63× objective 1.4 NA, using the following settings:
green channel for detecting FITC, excitation 488 nm argon laser,
emission bandpass ﬁlter 505–550 nm; blue channel for detecting
DAPI, excitation 405 nm blue diode laser, and emission bandpass
420–480 nm.
2.6. Western blotting analysis
Whole protein extracts were prepared by lysing cells in 50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS,
1 mM EDTA, 1% Igepal, 1× protease inhibitor (cat. n. 11836153001,
Roche Applied Science, Italy) and phosphatase inhibitor cocktail (cat.
n. 524627, Calbiochem, Italy). Protein concentration was determined
by the Bradford protein assay [53] using bovine serum albumin as
standard; identical amounts of proteins (30 μg) were subjected to 12%
SDS-PAGE performed as described by Laemmli [54].
For protein analysis on the conditioned medium, appropriate
volumes of concentrated samples corresponding to 100 μg total proteins
were loaded onto 12% or 7% reducing SDS-PAGE. After electrophoresis,
proteins were transferred to a nitrocellulose membrane (BA85;
Schleincher & Schull) and then incubated with the speciﬁc primary
antibody. In particular, the following antibodies were used:M
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(1:5000, cat. n. EP1254; cat. n. P08253, respectively, Epitomics,
Italy); p38 mitogen activated protein kinase (MAPK), phospho-p38
MAPK (Thr180/Tyr182) (1:2000 cat. n. 1544-1, and 1:5000, cat. n.
1229-1, respectively, Epitomics, Italy); glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (1:2000, cat. n. 14C10, Cell Signaling
Technology, Italy), the latter used as protein loading control;
– mouse monoclonal antibodies raised against uPA (1:1000, cat. n.
ab8473, Abcam, Cambridge, MA, USA) or Erk1/2 (1:1000, cat. n.
sc-135900, Santa Cruz Biotechnology, Italy);
– goat polyclonal antibodies raised against phospho-Erk1/2 (Thr202/
Tyr204) (1:1000, cat. n. sc-16982, Santa Cruz Biotechnology, Italy);
– homemade rabbit polyclonal antibodies (1:2000) [55] raised against
rat recombinant PN-1 [43]; humanprothrombin polyclonal antibodies
(1:2000, Nordic Immunological Laboratories, The Netherlands).
After incubation with the appropriate anti-mouse, anti-rabbit
(1:10000, cat. n. 31430 and cat. n. 31460, respectively, Pierce, Thermo
Scientiﬁc, Italy) or anti-goat (1:5000, cat. n. sc-2020, Santa CruzMMP-9
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Fig. 5. PN-1 silencing leads to increased MMP-9 and MMP-2 protein and mRNA expression lev
switched to the serum-free medium. After 48 h, cells were harvested for the preparation o
concentrated by ultraﬁltration, and volumes corresponding to 100 μg of cellular proteins w
immunoblotting analysis and ECL detection (A) or analyzed under nonreducing conditions th
for gelatin zymography (B). (C) Semi-quantitative RT-PCR analysis of MMP-9 and MMP-2 ex
used as internal control. The relative densitometric analysis is shown on the right side of each
from unsilenced cells, set as 1).Biotechnology, Italy) peroxidase-linked secondary antibody, detection
was achieved using Enhanced Chemiluminescence (ECL) kit (cat. n.
RPN 2209, GE Healthcare, Italy). Densitometric analysis was performed
using the free image-processing software ImageJ, version 1.47 (http://
rsb.info.nih.gov/ij/).
2.7. Gelatin and casein gel zymography
Gelatinolytic activity in the cell conditioned medium was detected
by SDS-PAGE zymography. Samples were analyzed under nonreducing
conditions without boiling, through a 7% SDS-polyacrylamide gel
co-polymerized in the presence of gelatin (1 mg/ml, cat. n. G1890,
Sigma-Aldrich, Italy) [56] for gelatinolytic zymography or through
a 12% SDS-polyacrylamide co-polymerized with casein (0.2%, cat. n.
C3400 Sigma-Aldrich, Italy) and bovine plasminogen (3.75 mU/ml,
cat. n. P9156, Sigma-Aldrich, Italy) for casein zymography [57].
After the electrophoresis run, carried out at 35 mA for 90–120 min
at 4 °C, the proteins in the gels were renatured in a 2.5% Triton X-100
solution for 1 h. The gels were then incubated with 50 mM Tris–HCl,M
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2638 V. Pagliara et al. / Biochimica et Biophysica Acta 1843 (2014) 2631–2644pH 7.5, 200 mM NaCl, 5 mM CaCl2 and 5 μM ZnCl2 at 37 °C for 48 h,
which allows substrate degradation. Finally, the gels were ﬁxed in 30%
methanol, 10% acetic acid for 30 min., stained with 0.5% Coomassie
Brillant Blue R-250. Proteolytic bands were visualized by destaining
with 50% methanol and 5% acetic acid. Gelatin zymography was also
performed in the presence of MMP-9 Inhibitor I (100 μM) [28] or
MMP-2 Inhibitor III (200 nM) [46] that were added during the
development of the gelatin gels.
2.8. Statistical analysis
Statistical signiﬁcance of samples against control or untreated cells
was determined by One-way analysis of Variance (ANOVA), followed
by the Dunnett's test. Each value represents the mean ± SEM of
at least three independent experiments performed in triplicate
(⁎p b 0.05; §p b 0.01; #p b 0.001).
3. Results
3.1. Construction of PN-1 shRNA expression plasmids
Recombinant pAVU6+27 plasmids encoding short hairpin RNA
(shRNA) were constructed to stably suppress PN-1 levels in C6 cells.
Three putative target sequences for siRNAs (D31, 2G and A7) were
identiﬁed in the upstream region of PN-1 cDNA by bioinformatic
analysis (Supplementary Fig. 1A). The corresponding nucleotide- 102
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Fig. 6. Exogenous recombinant PN-1 abolishesMMP-9 andMMP-2 gelatinase activity in D31.6 c
the absence or in the presence of exogenous rPN-1 (200 or 500 ng/ml). After 48 h, the condition
100 μg of cellular proteins were loaded onto 12% SDS-PAGE followed by PN-1 immunoblo
SDS-polyacrylamide gel co-polymerized in the presence of gelatin (1 mg/ml) for gelat
MMP-2 (empty bar) gelatinolytic activity on the conditioned medium from control or D3
as mean ± SEM, (n = 3). (#p b 0.001 statistically signiﬁcant from control or D31.6 cells
7% SDS-polyacrylamide gelatin zymography in the absence or in the presence of the selec
development of the gels (B, left panel). The relative densitometric analysis is also shown (B
signiﬁcant from D31.6 cells).sequences (Supplementary Fig. 1B) were used to generate pairs of
synthetic oligonucleotides, containing appropriate restriction sites
for successive vector cloning. The pAVU6+27 vector, containing
oneU6RNA-polymerase III promoter cassette and theﬁrst 27nucleotides
of human U6 RNA (Supplementary Fig. 2A), was digested with SalI and
XbaI restriction enzymes, to generate compatible ends for cloning. In
the resulting plasmids, the transcript was expected to fold into a
secondary structure to form a suitable target for anti-PN-1 shRNA,
composed by two aligned 19-nucleotide regions in an inverted
orientation separated by a 9-nucleotide loop (Supplementary Fig. 2B).
The shRNA expression vectors, namely pAVU6+27-PN-1-shD31
(pD31), pAVU6+27-PN-1-sh2G (p2G) and pAVU6+27-PN-1-shA7
(pA7) were subjected to DNA sequence analysis and tested for their
ability to knock-down PN-1 expression.3.2. PN-1 silencing by shRNA in C6 cells
To study the role of PN-1 in the migration and invasion capability
of glioma cells, we have ﬁrst analyzed the expression levels of PN-1
either on the serum-free cell conditioned medium (Fig. 1A, B) or
protein cell extracts (Supplementary Fig. 3A) from rat (C6) and
human glioblastoma–astrocytoma (A 172, U-87 MG, SW-1088 and
U-373 MG). Expression level of secreted PN-1 was higher in rat C6
cells in comparison with the other human cell lines analyzed; vice
versa, no signiﬁcant difference was observed in the cytosolic PN-1
espression levels (Supplementary Fig. 3A) among the cell linesM
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2639V. Pagliara et al. / Biochimica et Biophysica Acta 1843 (2014) 2631–2644analyzed. Therefore, C6 cells were used to silence PN-1 expression by
the generation of stable cell clones co-transfecting recombinant
shRNA PN-1 expression vectors (pA7, p2G or pD31) and pTK-Hygro
plasmid. A control cell line was generated by transfection with
pAVU6+27 empty vector (control, Ctrl cells). The effects of shRNA
on PN-1 expression in stable cell clones were evaluated by monitoring
both protein and mRNA levels by means of western blotting (Fig. 1C,
D and Supplementary Fig. 3B) and RT-qPCR analysis (Fig. 1E), respec-
tively. In particular, compared to the control clone, secreted PN-1 pro-
tein levels (Fig. 1C, D) were markedly reduced (~5 fold) in the
conditioned medium from D31.6 and 2G.2 cells. Moreover, in 2G.3
cells only a moderate decrease of the serpin was observed (~2 fold),
whereas in A7.6 cells only a minimal decrease (~1.5 fold) was found. It
has to be pointed out that the transfection with the empty
pAVU6+27 vector (control clone) had no effect on endogenous PN-1
levels, that were similar to those found in untransfected C6 cells. Fur-
thermore, PN-1 mRNA levels correlated well with the protein expres-
sion in each cell line (Fig. 1E). These results indicate that the RNA
interference approach silenced PN-1 expression, both at protein and
mRNA levels in C6 cells, although with different efﬁciencies among the
shRNAs analyzed. Finally, the two clones D31.6 and A7.6, representing
the more or the less effective at PN-1 silencing, respectively, were se-
lected for subsequent cellular and biochemical studies.
3.3. PN-1 silencing enhances migration and invasive activity in C6 glioma
cells
To determine the role of PN-1 in glioma cell migration and
invasiveness, Ctrl, A7.6 and D31.6 cells were subjected to the Boyden
chamber migration and matrigel invasion assays. The cells were platedA
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Fig. 7. Selective chemical MMP-9/2 inhibitors or exogenous rPN-1 reduce themigration and inv
matrigel invasion assays, in the absence (black bar) or in the presence of 25 nMMMP-9 Inhibito
were added to the upper and lower chambers. After 24 h, the cells at the bottom of the ﬁlters w
(A, C) and invasion (B, D) ability was quantiﬁed by counting the number of cells at the botto
presented as mean ± SEM (n = 3). (§p b 0.01; * p b 0.05, statistically signiﬁcant from untreatin the upper chamber of cell culture inserts uncoated or pre-coatedwith
matrigel and after 24 h incubation, the cells that had migrated or
invaded through the membranes were ﬁxed, stained and observed by
phase-contrast microscopy (Fig. 2A). D31.6 cells exhibited a signiﬁcant
increase (p b 0.001) in bothmigration (~2.5-fold) and invasive (~3-fold)
capabilities, compared to unsilenced cells (Fig. 2B). Vice versa, the
migration and invasive ability of A7.6 cells was only slightly higher
(~1.3-fold) than unsilenced cells. These results, besides conﬁrming
those obtained with the PN-1 silencing reported above, indicate that
the serpin is involved in themigration and invasive ability of glioma cells.
3.4. Effects of PN-1 silencing on thrombin and urokinase-type plasminogen
activator expression levels in C6 cells
Among PN-1 serine protease targets, thrombin and uPA are also
involved in tissue remodeling and tumor invasion [58,59]. The effects
of PN-1 silencing on thrombin expression levels were analyzed by
immunoblotting analysis on the conditioned medium from Ctrl, A7.6
and D31.6 cells (Fig. 3A). A polyclonal antibody against prothrombin
only recognized a single immunoreactive band, at about 72 kDa, corre-
sponding to the inactive zymogen and no signal corresponding to the
enzymatically active thrombin fragment (34 kDa) [60] was detected.
In addition, prothrombin expression levels were not altered by PN-1
silencing.
We also assessed uPA protein levels, enzyme activity and mRNA
expression on A7.6 and D31.6 cells. western blotting (Fig. 3B) showed
that D31.6 cells had a signiﬁcant increase (~2.5-fold) of uPA protein
levels, whereas A7.6 cells had only minimal variation with respect to
unsilenced cells. The observed increase of uPA protein levels correlated
with a higher enzyme activity (~4.3-fold) in comparison to A7.6 andInvasion assay
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2640 V. Pagliara et al. / Biochimica et Biophysica Acta 1843 (2014) 2631–2644unsilenced cells, as evaluated by casein zymography (Fig. 3C). Finally,
semiquantitative RT-PCR analysis (Fig. 3D) demonstrated only
a moderate increase in uPA mRNA levels in D31.6 and A7.6 cells com-
pared to unsilenced cells. These data indicate that PN-1 down-
regulation did not alter prothrombin expression levels whereas led to
a signiﬁcant increase of uPA protein expression levels and activity in
C6 glioma cells.B *
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(⁎p b 0.05) were shown.3.5. PN-1 silencing leads to an increase of MMP-9 and MMP-2 levels and
gelatinase activity in C6 cells
We also evaluated whether the enhancement in cell migration and
invasive ability involves MMP activity in PN-1 silenced C6 cells. To this
aim, we used in situ zymography (ISZ) that allows the localization of
cell gelatinase activity (Fig. 4). A stronger gelatinolytic activity (~2.5-*
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2641V. Pagliara et al. / Biochimica et Biophysica Acta 1843 (2014) 2631–2644fold increase) was detected in D31.6 cells compared to unsilenced cells,
in which a very weak ﬂuorescence signal was observed. To conﬁrm
these results, we performed rescue experiments in which D31.6 cells
were exposed to recombinant rat PN-1 (rPN-1) [43]. In particular,
the treatment for 24 h in the presence of 500 ng/ml rPN-1 led to a signif-
icant decrease of the ﬂuorescence intensity (~2.5-fold decrease, p
b 0.03) in comparison with untreated D31.6 cells (Fig. 4). The effect
was concentration dependent as at 200 ng/ml rPN-1 since only a
moderate reduction of the ﬂuorescence intensity (~1.8-fold decrease
at 24 h) was found (Supplementary Fig. 4). These results conﬁrmed
that the increase in cell gelatinolytic activity was due to PN-1
silencing.
Therefore, we evaluated whether the PN-1 down-regulation
would affect MMP-9 and MMP-2 protein and mRNA expression
levels (Fig. 5). The serum-free conditioned medium collected from
control, A7.6 and D31.6 cells were subjected to protein analysis by
western blotting (Fig. 5A) and evaluation of the enzyme activity by
SDS-PAGE gelatin zymography (Fig. 5B). Fig. 5A (left panel) showed
that in the conditioned medium of unsilenced cells, MMP-9 antibodies
revealed an immunoreactive doublet corresponding to pro-MMP-9
(98 kDa) and MMP-9 active form (92 kDa), respectively. The condi-
tioned medium from D31.6 cells showed an increase in MMP-9 protein
expression levels (~5.0-fold, p b 0.001) compared to unsilenced ones
(set as 1), whereas A7.6 cells only showed a moderate increase (~1.5-
fold, p b 0.001). In addition, D31.6 cells showed higher expression levels
(~3.5-fold, p b 0.001) of MMP-2 active form (66 kDa) and pro-MMP-2
(72 kDa) whereas A7.6 cells had a pro-MMP-2 expression levels similar
to unsilenced cells (Fig. 5A, right panel). It has to be pointed out that no
additional signals at differentmolecularmasswere revealed using these
antibodies (Supplementary Fig. 5).
The zymographic pattern (Fig. 5B, left panel) revealed gelatinolytic
components at molecular mass ranging from 100 to 80 kDa, expected
for MMP-9, and from 72 to 52 kDa for MMP-2. Furthemore, D31.6
cells showed a ~5-fold increase (p b 0.001) in gelatinase activity
compared to unsilenced cells whereas the conditioned medium from
A7.6 cells showed an activity similar (~1.5-fold) to control cells
(Fig. 5B, right panel).ECM
PN-1 in wild type C6 cells
plasma mem
LRP
complex
 degradation
PN-1
MMP-9/2
activation
plasminogen
plasmin
uPAR
uPA
MMP-9
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Fig. 9. Schematic model showing how PN-1 may inﬂuence the migration and invasiveness of C
enous PN-1 blocks uPA by the formation of stable complexes that are internalized through the
and MMP-9/2 protein levels, which enhance glioma cell migration and invasiveness through th
serine protease plasmin which generates active MMP-9/2 from their inactive zymogens [20]. F
signaling involved in the phosphorylation of Erk1/2 and p38 MAPK [33,40].We also determined whether PN-1 down-regulation affects the
expressionofMMP-9/2 at the transcriptional level using semiquantitative
RT-PCR analysis (Fig. 5C). D31.6 cells exhibited an increase in MMP-9
(~3.2-fold, p b 0.001) and MMP-2 (~2.5-fold, p b 0.001) mRNA
expression levels compared to control cells, whereas A7.6 cells had
a MMP-9 and MMP-2 mRNA expression levels similar to unsilenced
cells. Taken together, these results indicate that PN-1 regulates the
expression of MMP-9 and MMP-2 at both transcriptional and
translational levels in C6 glioma cells.
3.6. Exogenous recombinant PN-1 restores the gelatinolytic activity in PN-1
silenced glioma
To conﬁrm that the down-regulation of endogenous PN-1 levels is
responsible for an increased gelatinolytic activity in D31.6 cells, we
performed rescue experiments employing exogenous recombinant
PN-1 (rPN-1) [43]. To this aim, rPN-1 (200 or 500 ng/ml) was
added to the serum-free medium in D31.6 cells and after 48 h, the
conditioned medium was subjected to western blotting analysis to
evaluate PN-1 protein levels and gel zymography (Fig. 6). Exogenous
recombinant PN-1 was able to abolish the increase in the gelatinase
activity observed in the conditioned medium of D31.6 cells (Fig. 6A).
In particular, the exposure to 200 ng/ml rPN-1 induced a strong reduc-
tion inMMP-9 gelatinolytic activity (~4-fold, p b 0.001), whereas slight
differences were observed in MMP-2 gelatinolytic activity compared to
unexposed cells. Moreover, rPN-1 at 500 ng/ml was able to reduce also
MMP-2 activity (~3.8-fold, p b 0.001) to the basal level observed in
unsilenced cells. The differences observed between MMP-9 and MMP-
2 gelatinolytic activities, correlated to the different expression levels
reported in Fig. 5.
In addition, the presence of a PN-1 immunoreactive fragment
(~37 kDa) in the conditioned medium of D31.6 cells incubated
with 500 ng/ml rPN-1 was found. This fragment can be derived
from a proteolytic cleavage by a target protease. To conﬁrm that the
increase in gelatinase activity in D31.6 cells was mainly due to MMP-9
and/or MMP-2, selective chemical inhibitors for MMP-9 (Inhibitor I,
100 μM) [28] or MMP-2 (Inhibitor III, 200 nM) [46] were used whilePN-1 silencing in C6 cells
nucleus
p-Erk1/2
p-p38 MAPK
MMP-9/2 transcription
brane
ECM
 migration/invasion
ECM degradation
uPA
plasminogen
plasmin
PN-1
pro-MMP-9/2
pro-MMP-9/2
active MMP-9/2
6 glioma cells. In the extra-cellular environment of wild type C6 cells (left panel), endog-
LRP receptor and degraded [6,29]. PN-1 silencing (right panel), leads to an increase in uPA
e degradation of ECM components; uPA converts the inactive plasminogen into the active
urther, PN-1 might affect MMP-9 transcription by a possible interference with upstream
2642 V. Pagliara et al. / Biochimica et Biophysica Acta 1843 (2014) 2631–2644developing SDS-PAGE zymography (Fig. 6B). These inhibitors were able
to abolish the gelatinase activity thus conﬁrming the identity of MMP-9
and MMP-2 in the zymographic pattern. Taken together, these results
conﬁrm that PN-1 silencing enhances MMP-9 and MMP-2 gelatinolytic
activity in the conditioned medium from C6 cells.
3.7. Selective inhibitors of MMPs or exogenous rPN-1 reduced migration
and invasive ability in PN-1 silenced C6 cells
To conﬁrm the role of MMP-9 and MMP-2 in the enhanced cell
migration and invasive ability in PN-1 silenced C6 cells, migration and
invasion assayswere also performed in the presence ofMMP-9 Inhibitor
I, (25 nM, ﬁnal concentration) [28], MMP-2 Inhibitor III (60 nM, ﬁnal
concentration) [46] or rPN-1 (500 ng/ml) [43] which were added
to the medium in the upper and lower compartments of the Boyden
chambers. The results demonstrated that these inhibitors effectively
suppressed the migration ability (Fig. 7A) and the invasiveness (Fig. 7B)
of D31.6 cells that showed a behavior similar to that of unsilenced ones.
In fact, we observed a reduction in the numbers of D31.6 cells that had
migrated (~2.8 fold, Fig. 7A) or invaded (~2.5 fold, Fig. 7B) in comparison
to the untreated D31.6 cells. Conversely, A7.6 cells showed a minimal
decrease either in migration or invasion capability. In addition, the expo-
sure to rPN-1 reverted this behavior (Fig. 7C, D), although to a lower
extent compared to MMP inhibitors. These results clearly support the
hypothesis that PN-1 affects cell migration and invasive capability
through the regulation of MMP-9 and MMP-2 expression levels in C6
glioma cells.
3.8. PN-1 silencing stimulates Erk1/2 and p38 MAPK signaling in C6 cells
Previous studies reported that the MAPK family, including Erk
and p38, is involved in cancer cell invasion triggered by MMP-9 and
MMP-2 [33,40]. Thus, we investigated whether the enhancement
in cell migration and invasiveness mediated by the modulation of
MMP-9/2 expression in PN-1 silenced cells, may involve Erk and p38
MAPK signaling pathways.Western blotting analysis (Fig. 8) performed
on cell lysates from Ctrl, A7.6 and D31.6 cells, in the presence or in the
absence of MMP-9 Inhibitor I (25 nM) [28] and MMP-2 Inhibitor III
(60 nM) [46] (Fig. 8A, B) showed that Erk1/2 and p38 phosphorylation
levels were signiﬁcantly increased in D31.6 cells (~2.0 and 2.5-fold,
respectively, p b 0.01) compared to unsilenced cells, whereas in A7.6
cells no difference was found. The treatment with either MMP-9
Inhibitor I or MMP-2 Inhibitor III almost completely abolished Erk1/2
and p38 phosphorylation. Furthermore, the treatment of D31.6 cells
with rPN-1 (500 ng/ml) [43] (Fig. 8 C, D) also abolished the increase
in the phosphorylation of both Erk1/2 and p38 caused by PN-1 silencing.
Taken together, these results indicate that the down-regulation of PN-1
may enhance glioma cell migration and invasion via Erk1/2 and p38
pathways in C6 cells.
4. Discussion
Glioblastomamultiforme (GBM) is themost common and aggres-
sive tumor in CNS with a poor clinical outcome due to the highly
invasive potential [34]. The rat C6 glioma cell line [35], expressing
endogenous PN-1 [9], shows many characteristics of GBM and has
been used as an in vitro system model to investigate factors involved
in the growth and invasiveness of glioblastoma cells [36,58]. Because
serpins have been proposed to have a protective role against tumor
invasion by the inhibition of serine–protease activity, we evaluated
the effects of PN-1 silencing on the migration and invasive ability
of C6 cells. Our results indicate that the PN-1 down-regulation
enhances the migration and invasiveness in stable C6 cells. Notably,
D31 cells with a signiﬁcant reduction in PN-1 expression levels also
showed a higher migration and invasive capability (Fig. 2). These
results are in line with data by Xu et al. [29] that demonstrated thatprostate cancer cells, PC3-ML over-expressing PN-1, had a reduced
invasiveness in matrigel assay therefore indicating that PN-1 may
act as a negative regulator of invasive potential in prostate and
glioma cells. On the contrary, previous studies indicated that PN-1
exhibits pro-invasive functions in mammary [33], colorectal [41],
and pancreatic [26] cancer cell lines. Since the invasive ability of
tumor cells depends from a critical balance between proteases and
their inhibitors in the ECM [14], PN-1 might interact with proteases
or other target molecules depending from the cell micro-environment.
Among PN-1 target serine proteases, thrombin and uPA are key
enzymes in tissue remodeling [17–19] that occurs in physiological
processes and tumor invasion [16]. In the brain, PN-1 is the main
physiological inhibitor of thrombin, a protease involved in the coag-
ulation cascade but also recently known for its role in tumor cell
invasion and modulation of MMP expression [17,58,61]. However,
control and PN-1 silenced C6 cells expressed similar levels of the
zymogen prothrombin (72 kDa; Fig. 3A) whereas enzymatically
active thrombin was not detected [62]. Therefore, thrombin inhibition
by PN-1 seems to be not involved in the migration and invasiveness of
C6 glioma cells, consistent with a previous study in the same cell line
[58]. In C6 cells, the down-regulation of PN-1 led to increased uPA pro-
tein levels and caseinolytic activity, although no effect was observed
at the transcriptional level (Fig. 3C, D) suggesting that PN-1 has little
effect on the transcriptional regulation of uPA expression.
PN-1 silencing induced an increase in both cell gelatinolytic activity
(Fig. 4 and Supplementary Fig. 4) and MMP-9 expression and
gelatinolytic activity, that were signiﬁcantly enhanced in the culture
medium from D31.6, where a more efﬁcient PN-1 down-regulation
was achieved (Fig. 5). Notably, it was also found that PN-1 silencing
could up-regulate MMP-2 expression and gelatinolytic activity.
Furthermore, these effects were reverted in the presence of selective
chemical MMP-9/2 inhibitors as well as by the exposure to exogenous
rPN-1. In addition, the migration and invasive potential of D31.6 cells
(Fig. 7) were restored to the basal level after the exposure to the
above-mentioned inhibitors/rPN-1.
These ﬁndings are in line with data of Xu et al. [29] and consistent
with the hypothesis that in C6 cells, PN-1 signiﬁcantly prevents cell
migration and invasiveness through the regulation of uPA, MMP-9
and MMP-2 expression levels. Furthermore, in C6 cells, MMP-9 may be
regulated by PN-1 at transcriptional levels through the activation of
Erk1/2 in D31.6 cells (Fig. 8) as well as at post-transcriptional levels; in
fact, in ECM PN-1 may become a substrate for MMP-9 [28].
However, other studies using mammary tumor models [25] and
pancreatic cell tumors in mice models [26] have indicated that the
over-expression of PN-1 enhanced the invasive potential, whereas the
loss of PN-1 causes adecrease inMMP-9 levels [33]. These controversial re-
sults on PN-1 functionsmay be attributable to the different roles played by
this serpin depending on the speciﬁc cell micro-environment. In fact, since
PN-1 is a secreted serpin, its protein levels may affect the biological func-
tions of speciﬁc target molecules present in the extracellular environ-
ment of C6 glioma cells. In summary, our results suggest that in C6
glioma cells PN-1 exerts an anti-invasive effect through the regulation
of uPA level [20], which induces MMP-9/2 activation in the extra-
cellular environment (Fig. 9, left panel). The down-regulation of PN-1
endogenous levels led to increased amount of uPA that generates active
MMP-9/2 through the activation of plasmin [20] thus enhancingmigra-
tion and invasive potential of C6 glioma cells (Fig. 9, right panel). How-
ever, themolecularmechanismwhereby PN-1 could regulateMMP-9 at
the transcriptional level, requires further investigations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.07.008.
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